title: An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function.
abstract: Hepatitis C virus (HCV) infection affects roughly 170 million people worldwide. Sofosbuvir/Ledipasvir (Sof/Led) is a new once daily direct acting antiviral combination pill that was approved in October 2014 for use in patients with HCV genotype 1 infection. Coadministration of Sof/Led is studied only with rosuvastatin which shows significantly increased level of drug and is associated with increased risk of myopathy, including rhabdomyolysis. There is no mention of such HMG-CoA reductase inhibitor interaction as a class, as pravastatin did not have any clinically significant interaction with Sof/Led. Other myotoxic drugs, including colchicine are not studied. We present a case of a serious drug interaction between Sof/Led and atorvastatin, in the background of CKD and colchicine use.
authors.affiliation: Department of Medicine, Temple University Hospital, Philadelphia, PA 19140, USA.
authors.forename: Shyam
authors.identifier: 0000-0002-7673-4014
authors.initials: S
authors.lastname: Patel
authors.affiliation: Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, PA 19140, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Andres
authors.affiliation: Department of Medicine, Section of Gastroenterology, Temple University Lewis Katz School of Medicine, 3440 N. Broad Street, Philadelphia, PA 19140, USA.
authors.forename: Kamran
authors.identifier: 0000-0002-3597-9576
authors.initials: K
authors.lastname: Qureshi